Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 802 across all filing types
Latest filing 2007-07-20 Interim / Quarterly Rep…
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
Pharming announces first half 2007 results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half of 2007 (HY1 2007), containing detailed management commentary, operational updates, and actual financial statements (Consolidated Balance Sheet and Consolidated Income Statement). It is not merely an announcement of a report, as it provides the substantive financial data itself. Therefore, it is classified as an Interim/Quarterly Report. H1 2007
2007-07-20 English
Pharming announces first half 2007 results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first half (H1) of 2007, containing detailed management commentary, operational updates, and consolidated financial statements (balance sheet and income statement). It is not merely an announcement of a report, as it provides substantive financial data and analysis. Therefore, it is classified as an Interim/Quarterly Report. H1 2007
2007-07-20 English
Pharming facilities obtain GMP status
Regulatory Filings Classification · 95% confidence The document is a press release dated July 13, 2007, announcing that Pharming Group NV's facilities have obtained Good Manufacturing Practice (GMP) status from the European Medicines Evaluation Agency (EMEA) for the manufacturing of Rhucin®. It details operational progress, regulatory steps (MAA submission), and future clinical trial timelines. This type of announcement, focusing on a specific operational or regulatory milestone outside of routine financial reporting (like earnings or annual reports), fits best under a general regulatory or corporate announcement category. Since it is not a formal financial report (10-K, IR, ER, MRQ), nor a management change (MANG), nor a specific legal filing (LTR), nor a dividend notice (DIV), it is classified as a general Regulatory Filing (RNS), which serves as the catch-all for significant, non-standard corporate news releases.
2007-07-13 English
Pharming facilities obtain GMP status
Regulatory Filings Classification · 90% confidence The document is a press release from Pharming Group NV dated July 13, 2007, announcing that its production facilities for Rhucin® have successfully passed the Good Manufacturing Practice (GMP) inspection by the European Medicines Agency (EMEA). It discusses regulatory progress (EMEA review timeline, expected US clinical trial completion, and presentation of HAE results in Q3 2007). This type of announcement, detailing significant operational milestones, regulatory progress, or key business updates outside of standard periodic financial reports (10-K, IR) or specific corporate actions (DIV, CAP), typically falls under a general regulatory announcement or a specific business update. Since it is a formal announcement of a major operational/regulatory milestone (GMP approval) and not a full financial report, earnings release, or a standard regulatory filing like a 10-K, it best fits the category for general regulatory announcements or significant corporate news. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a significant, non-standard corporate announcement, although it strongly resembles an Earnings Release (ER) in structure, it focuses on operational/regulatory approval rather than financial results highlights. However, since it is a specific announcement about a regulatory/operational milestone (GMP status) that directly impacts future product approval, and it is not a full financial report, 'Regulatory Filings' (RNS) serves as the best fit for a non-standard, material announcement.
2007-07-13 English
Pharming Provides Portfolio And Technology Update At Company Meeting
Report Publication Announcement Classification · 99% confidence The document is titled 'PHARMING PROVIDES PORTFOLIO AND TECHNOLOGY UPDATE AT COMPANY MEETING' and details presentations given by various executives and scientific advisors regarding product pipelines (Rhucin, lactoferrin, fibrinogen), clinical trial status, and regulatory interactions (FDA GRAS, EMEA MAA). This content strongly suggests an Investor Presentation (IP) or a detailed update presentation, rather than a formal regulatory filing like a 10-K or an Earnings Release (ER) which focuses on period results. Since it describes the content of a specific meeting/presentation for analysts and reporters, 'Investor Presentation' (IP) is the most appropriate classification.
2007-06-28 English
Pharming Provides Portfolio And Technology Update At Company Meeting
Regulatory Filings Classification · 95% confidence The document is a press release dated June 28, 2007, titled "PHARMING GEEFT UPDATE OVER PIJPLIJN EN TECHNOLOGIE TIJDENS BEDRIJFSBEZOEK" (Pharming Gives Update on Pipeline and Technology During Business Visit). It details presentations given by management and scientific advisors regarding product pipeline updates (Rhucin, lactoferrin, fibrinogen), scientific background, and regulatory progress (FDA GRAS status, EMEA review). This content strongly aligns with an Investor Presentation (IP) or a detailed Management Discussion/Update, rather than a formal regulatory filing like a 10-K or an Earnings Release (ER) which focuses strictly on period results. Since it describes presentations given at an analyst/journalist event covering strategy, pipeline, and technology, Investor Presentation (IP) is the most appropriate classification. It is not a formal AGM material (AGM-R) or a simple announcement of a report (RPA).
2007-06-28 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.